Eagle Genomics announces Advisory Board formation
6.7.2017 19:29 | Business Wire
Smart data management company, Eagle Genomics, is pleased to announce the formation of an Advisory Board comprised of some of the world’s thought leaders in data and life sciences. Members of the board are all exceptional individuals representing enterprise, academia, investment and education.
The purpose of the Advisory Board is to further the Company’s mission to enable insight through data driven discovery, with members offering specialised scientific expertise to the executive management team.
Founding members of the Advisory Board include Nessa Carey, Douglas Kell CBE, Researcher and Systems Biologist at the University of Manchester, Cliff Meltzer, CEO at Excellcare, David Cleevely CBE, Chairman at Raspberry Pi Foundation and Paul Flicek, Head of Genes, Genomes and Variation Resources at European Bioinformatics Institute.
“Each advisor brings a wealth of knowledge, experience, and a valuable external perspective to ensure Eagle Genomics remains at the forefront of scientific innovation,” said Executive Chairman Anthony Finbow.
Providing a combination of software and bioinformatics expertise, the Eagle Genomics platform acts as the “Automated Data Scientist”, qualifying and collating the relevant data from which faster and more accurate insight can be achieved.
The company also announce the retirement of Alan Barrell as Non-Executive Director. Chairman Anthony Finbow commented: “I would personally like to thank Alan for his years of service and the valuable contribution he has made to Eagle, and wish him a healthy, happy retirement.”
Further details of the Advisory Board members are given on the Eagle Genomics website.
About Eagle Genomics
Eagle Genomics is a smart data management software company helping life sciences companies conducting data intensive research to bring new candidate medicines, therapies and products to patients and customers more quickly. Its Automated Data Scientist software platform exploits state of the industry data science to radically reduce time to cost of research, thus enabling customers to achieve drastic productivity improvements and true data driven discovery.
For more information on Eagle Genomics, please visit the company’s website, follow Eagle Genomics on Twitter (@Eaglegen) or call Eagle Genomics at +44 (0)1223 654481.
UK +44 7719 622303
USA +1 914 215 4345
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Vertex Expands Cloud Platform in Response to Market Demand24.7.2017 19:28 | Tiedote
Vertex, Inc. today announced it is significantly expanding the capabilities and reach of its cloud platform. Success in the $500 million and below market, the need for more efficient and agile technology in the tax space and significant growth in cloud adoption are fueling enterprise cloud expansion. This enhanced offering, Vertex® Cloud Indirect Tax, runs on the most advanced tax calculation and returns software platform in the industry, used by thousands of businesses from the largest corporations in the world to the smallest ecommerce businesses. Vertex Cloud is right-sized for any organization and is positioned to support all sales and use tax needs. Benefits of Vertex Cloud include: Extended functionality for all types of businesses across the globe; Reduced time and effort to perform tax calculations and returns;
Larsen & Toubro Infotech Limited (LTI) Announces: Net Profit Jumps 5% QoQ; USD Revenue Growth up 2% QoQ and 12% YoY24.7.2017 17:47 | Tiedote
Larsen & Toubro Infotech (BSE code: 540005)(NSE: LTI), a global technology consulting and digital solutions company, announced its Q1 FY18 results today. In US Dollars: Revenue at USD 259.2 million; growth of 2.0% QoQ and 12.2% YoY Constant Currency Revenue growth of 1.5% QoQ and 11.8% YoY In Indian Rupees: Revenue at Rs 16,707 million; decline of 0.4% QoQ and growth of 7.4% YoY Net Income at Rs 2,672 million; Net Income growth of 5.0% QoQ and 13.3% YoY “We continue our growth trajectory with a 2% QoQ increase in USD revenues, reflecting the resilience of our portfolio. Digital Services and Infrastructure Managem
Moody’s Analytics Voted Best Credit Risk Solution Provider in Waters Rankings for Second Year in a Row24.7.2017 17:00 | Tiedote
Moody’s Analytics today announced that it has been voted “Best Credit Risk Solution Provider” for its RiskCalc™ solution in the 2017 Waters Rankings. The RiskCalc solution provides a global suite of models for evaluating commercial and industrial credit risk. 2017 marks the second straight year that Moody’s Analytics has won the “Best Credit Risk Solution Provider” category in the Waters Rankings. Each year, these rankings are determined through a poll of the readers of Waters magazine, a financial IT publication with a readership of over 10,000 professionals. “We are proud that industry practitioners have again recognized RiskCalc software as the best credit risk solution,” said Mehna Raissi, Senior Director-Product Management at Moody’s Analytics. “This honor reflects the value our clients receive from using RiskCalc software. We understand our customers’ challenges, the r
Synectics Wins European Contract for Train-to-Ground ‘Passenger Help’ Solution24.7.2017 16:59 | Tiedote
Synectics is to develop a train-to-ground solution that will enable a major European rapid transit operator to receive, manage and respond to on-vehicle passenger help requests remotely, from a central command center. Following a year-long competitive tender process ‒ which identified Synectics as the most suitable provider to deliver against the technical requirements involved ‒ the global surveillance specialist has been chosen to design and deploy the tailored solution across 680 trains servicing the capital city. To answer the brief, Synectics has developed an “audio gateway” hardware solution which interfaces with the customer’s on-vehicle passenger help system to enable audio in/audio out transmission via the train’s cellular modem. Using Synectics’ Synergy command and control platform to integrate the communications data, authorized personnel based a
Calvin Klein, Inc. Announces Fall 2017 CALVIN KLEIN 205W39NYC Global Advertising Campaign24.7.2017 16:00 | Tiedote
Calvin Klein, Inc., a wholly owned subsidiary of PVH Corp. [NYSE: PVH], today announced the Fall 2017 CALVIN KLEIN 205W39NYC global multi-media advertising campaign. The campaign features the debut CALVIN KLEIN 205W39NYC collection by Chief Creative Officer Raf Simons. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170724005416/en/ FALL 2017 CALVIN KLEIN 205W39NYC GLOBAL ADVERTISING CAMPAIGN (Photo: © 2017 Willy Vanderperre) Shot by photographer Willy Vanderperre, the visually striking campaign presents a cast of 22 models shot against a series of billboards that feature images from last season’s CALVIN KLEIN: American Classics campaign. The billboards of the previous campaign – which include works by artist Andy Warhol – were erected in the California desert in the days le
Samsung Bioepis Announces RENFLEXIS™ (infliximab-abda) Now Available in the United States24.7.2017 15:04 | Tiedote
Samsung Bioepis Co., Ltd. today announced the launch of RENFLEXIS ™ (infliximab-abda), a biosimilar referencing Remicade® (infliximab), in the United States (US). RENFLEXIS ™ was developed by Samsung Bioepis, and is being commercialized in the US by Merck, which is known as MSD outside of the US and Canada. RENFLEXIS™ was approved by the US Food and Drug Administration (FDA) in April 2017. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170724005616/en/ Christopher Hansung Ko, President & CEO of Samsung Bioepis. (Photo: Business Wire) “Since we were established five years ago, we have strived to bring high-quality treatment options at a lower cost to US patients. RENFLEXIS is our first step in meeting this important commitment,” said Christopher Hans
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme